SK3462002A3 - Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins - Google Patents

Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins Download PDF

Info

Publication number: SK3462002A3
Authority: SK; Slovakia
Prior art keywords: estramustine phosphate; sulfoalkyl ether; cancer; cyclodextrin; pharmaceutical composition
Prior art date: 1999-09-16

Application number

SK346-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Lorena Muggetti

Paolo Colombo

Alessandro Martini

Giovanni Buzzi

Original Assignee

Pharmacia Italia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-16

Filing date

2000-08-03

Publication date

2002-08-06

2000-08-03 Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa

2002-08-06 Publication of SK3462002A3 publication Critical patent/SK3462002A3/sk

Links

ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 title claims abstract description 56
229960004750 estramustine phosphate Drugs 0.000 title claims abstract description 54
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title claims abstract description 54
229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 31
239000000203 mixture Substances 0.000 title abstract description 36
238000009472 formulation Methods 0.000 title abstract description 25
-1 sulfoalkyl ether Chemical compound 0.000 title description 8
229940097362 cyclodextrins Drugs 0.000 title description 4
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 26
125000004964 sulfoalkyl group Chemical group 0.000 claims abstract description 25
238000002347 injection Methods 0.000 claims abstract description 13
239000007924 injection Substances 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
229940127089 cytotoxic agent Drugs 0.000 claims abstract description 9
239000002246 antineoplastic agent Substances 0.000 claims abstract description 8
239000003085 diluting agent Substances 0.000 claims abstract 3
229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 16
238000001990 intravenous administration Methods 0.000 claims description 12
230000000694 effects Effects 0.000 claims description 8
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 7
238000001802 infusion Methods 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 4
239000011780 sodium chloride Substances 0.000 claims description 4
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
208000003174 Brain Neoplasms Diseases 0.000 claims description 3
206010006187 Breast cancer Diseases 0.000 claims description 3
208000026310 Breast neoplasm Diseases 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
208000025865 Ulcer Diseases 0.000 claims description 3
238000011319 anticancer therapy Methods 0.000 claims description 3
230000003902 lesion Effects 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
201000001441 melanoma Diseases 0.000 claims description 3
201000002528 pancreatic cancer Diseases 0.000 claims description 3
208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
201000005060 thrombophlebitis Diseases 0.000 claims description 3
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
229940123237 Taxane Drugs 0.000 claims description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
229940127093 camptothecin Drugs 0.000 claims description 2
229960004562 carboplatin Drugs 0.000 claims description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
229960004316 cisplatin Drugs 0.000 claims description 2
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
229960004679 doxorubicin Drugs 0.000 claims description 2
229960001904 epirubicin Drugs 0.000 claims description 2
229960005420 etoposide Drugs 0.000 claims description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
229960000908 idarubicin Drugs 0.000 claims description 2
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
229940086322 navelbine Drugs 0.000 claims description 2
229960003048 vinblastine Drugs 0.000 claims description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 7
239000003814 drug Substances 0.000 claims 2
206010028980 Neoplasm Diseases 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
239000002502 liposome Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
238000009104 chemotherapy regimen Methods 0.000 abstract description 2
231100000957 no side effect Toxicity 0.000 abstract 1
239000000243 solution Substances 0.000 description 15
239000004480 active ingredient Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
241000700159 Rattus Species 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 5
230000007794 irritation Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000002254 cytotoxic agent Substances 0.000 description 3
231100000599 cytotoxic agent Toxicity 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
XCRFEYAXJYXVHT-HLZMRHSNSA-N CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 XCRFEYAXJYXVHT-HLZMRHSNSA-N 0.000 description 1
229940123587 Cell cycle inhibitor Drugs 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229940078123 Ras inhibitor Drugs 0.000 description 1
108010017842 Telomerase Proteins 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000002942 anti-growth Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
229960001842 estramustine Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229940124541 immunological agent Drugs 0.000 description 1
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000012931 lyophilized formulation Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK346-2002A 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins SK3462002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9921958.6A GB9921958D0 (en)	1999-09-16	1999-09-16	Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
PCT/EP2000/007680 WO2001019339A1 (en)	1999-09-16	2000-08-03	Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

Publications (1)

Publication Number	Publication Date
SK3462002A3 true SK3462002A3 (en)	2002-08-06

Family

ID=10861068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK346-2002A SK3462002A3 (en)	1999-09-16	2000-08-03	Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

Country Status (19)

Country	Link
US (1)	US6730664B1 (cs)
EP (1)	EP1212041A1 (cs)
JP (1)	JP2003509356A (cs)
KR (1)	KR20020059401A (cs)
CN (1)	CN1374857A (cs)
AU (1)	AU777684B2 (cs)
BR (1)	BR0014062A (cs)
CA (1)	CA2385065A1 (cs)
CZ (1)	CZ2002944A3 (cs)
EA (1)	EA003936B1 (cs)
GB (1)	GB9921958D0 (cs)
HU (1)	HUP0300185A3 (cs)
IL (1)	IL148408A0 (cs)
MX (1)	MXPA02002855A (cs)
NO (1)	NO20021270D0 (cs)
PL (1)	PL356026A1 (cs)
SK (1)	SK3462002A3 (cs)
WO (1)	WO2001019339A1 (cs)
ZA (1)	ZA200201744B (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6869939B2 (en) *	2002-05-04	2005-03-22	Cydex, Inc.	Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US7658913B2 (en)	2005-11-28	2010-02-09	Verrow Pharmaceuticals, Inc.	Compositions useful for reducing nephrotoxicity and methods of use thereof
NZ592293A (en) *	2005-11-28	2012-10-26	Verrow Pharmaceuticals Inc	Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs
US20110207764A1 (en) *	2010-02-23	2011-08-25	Valery Alakhov	Cyclopolysaccharide compositions
US8383663B2 (en)	2010-07-19	2013-02-26	Supratek Pharma Inc.	Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP4598589A1 (en) *	2022-10-05	2025-08-13	Institut Gustave Roussy	An oral liquid composition of vinorelbine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1523035A (en) *	1976-03-10	1978-08-31	Leo Ab	Derivatives of estradiol - 17 - dihydrogen phosphates
JPS59108800A (ja)	1982-12-13	1984-06-23	Japan Atom Energy Res Inst	誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
CA1260393A (en) *	1984-10-16	1989-09-26	Lajos Tarcsay	Liposomes of synthetic lipids
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602112A (en) *	1992-06-19	1997-02-11	Supergen, Inc.	Pharmaceutical formulation
GB9419153D0 (en) *	1994-09-22	1994-11-09	Erba Carlo Spa	Estramustine formulations with improved pharmaceutical properties
US5744460A (en) *	1996-03-07	1998-04-28	Novartis Corporation	Combination for treatment of proliferative diseases
US20020039594A1 (en)	1997-05-13	2002-04-04	Evan C. Unger	Solid porous matrices and methods of making and using the same

1999
- 1999-09-16 GB GBGB9921958.6A patent/GB9921958D0/en not_active Ceased
2000
- 2000-08-03 CN CN00812947A patent/CN1374857A/zh active Pending
- 2000-08-03 MX MXPA02002855A patent/MXPA02002855A/es unknown
- 2000-08-03 PL PL00356026A patent/PL356026A1/xx unknown
- 2000-08-03 US US10/070,416 patent/US6730664B1/en not_active Expired - Fee Related
- 2000-08-03 HU HU0300185A patent/HUP0300185A3/hu unknown
- 2000-08-03 AU AU69939/00A patent/AU777684B2/en not_active Ceased
- 2000-08-03 JP JP2001522974A patent/JP2003509356A/ja not_active Withdrawn
- 2000-08-03 EP EP00958398A patent/EP1212041A1/en not_active Withdrawn
- 2000-08-03 IL IL14840800A patent/IL148408A0/xx unknown
- 2000-08-03 CA CA002385065A patent/CA2385065A1/en not_active Abandoned
- 2000-08-03 WO PCT/EP2000/007680 patent/WO2001019339A1/en not_active Ceased
- 2000-08-03 KR KR1020027003383A patent/KR20020059401A/ko not_active Withdrawn
- 2000-08-03 SK SK346-2002A patent/SK3462002A3/sk unknown
- 2000-08-03 EA EA200200370A patent/EA003936B1/ru not_active IP Right Cessation
- 2000-08-03 CZ CZ2002944A patent/CZ2002944A3/cs unknown
- 2000-08-03 BR BR0014062-7A patent/BR0014062A/pt not_active IP Right Cessation
2002
- 2002-03-01 ZA ZA200201744A patent/ZA200201744B/en unknown
- 2002-03-14 NO NO20021270A patent/NO20021270D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0300185A3 (en)	2007-02-28
KR20020059401A (ko)	2002-07-12
CN1374857A (zh)	2002-10-16
HUP0300185A2 (en)	2003-05-28
US6730664B1 (en)	2004-05-04
NO20021270L (no)	2002-03-14
NO20021270D0 (no)	2002-03-14
AU6993900A (en)	2001-04-17
EP1212041A1 (en)	2002-06-12
CA2385065A1 (en)	2001-03-22
EA003936B1 (ru)	2003-10-30
CZ2002944A3 (cs)	2002-08-14
JP2003509356A (ja)	2003-03-11
WO2001019339A1 (en)	2001-03-22
MXPA02002855A (es)	2003-07-21
IL148408A0 (en)	2002-09-12
AU777684B2 (en)	2004-10-28
GB9921958D0 (en)	1999-11-17
PL356026A1 (en)	2004-05-31
EA200200370A1 (ru)	2002-10-31
ZA200201744B (en)	2004-01-28
BR0014062A (pt)	2002-12-31

Publication	Publication Date	Title
SK3442002A3 (en)	2002-09-10	Formulations for parenteral use of estramustine phosphate and amino acids
SK3462002A3 (en)	2002-08-06	Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
NZ517632A (en)	2004-02-27	Formulations for parenteral use of estramustine phosphate and albumin
SK3452002A3 (en)	2002-08-06	Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ZA200201955B (en)	2003-05-28	Formulations for parenteral use of estramustine phosphate and albumin.
HK1048946A (en)	2003-04-25	Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
HK1063153A (en)	2004-12-17	Formulations for parenteral use of estramustine phosphate and albumin